Advertisement

Topics

Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 Pipeline Review, H1 2017

Summary

Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 Leukotriene A4 hydrolase LTA4H is an enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTB4 is a potent lipid chemoattractant involved in inflammation, immune responses, host defense against infection and PAFinduced shock.

Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Cardiovascular, Respiratory, Dermatology and Hematological Disorders which include indications Pulmonary Arterial Hypertension, Acne Vulgaris, Chronic Obstructive Pulmonary Disease COPD, Cystic Fibrosis, Emphysema and Lymphedema.

The latest report Leukotriene A 4 Hydrolase Pipeline Review, H1 2017, outlays comprehensive information on the Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6
The report reviews Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics and enlists all their major and minor projects
The report assesses Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Leukotriene A 4 Hydrolase LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...